KR20250004890A - 사이클린 의존성 키나제 저해제로서의 치환된 6-(피리미딘-4-일)퀴놀린 화합물 - Google Patents
사이클린 의존성 키나제 저해제로서의 치환된 6-(피리미딘-4-일)퀴놀린 화합물 Download PDFInfo
- Publication number
- KR20250004890A KR20250004890A KR1020247039643A KR20247039643A KR20250004890A KR 20250004890 A KR20250004890 A KR 20250004890A KR 1020247039643 A KR1020247039643 A KR 1020247039643A KR 20247039643 A KR20247039643 A KR 20247039643A KR 20250004890 A KR20250004890 A KR 20250004890A
- Authority
- KR
- South Korea
- Prior art keywords
- heterocyclyl
- alkynyl
- alkenyl
- heteroaryl
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022090344 | 2022-04-29 | ||
| CNPCT/CN2022/090344 | 2022-04-29 | ||
| CNPCT/CN2022/105964 | 2022-07-15 | ||
| CN2022105964 | 2022-07-15 | ||
| CNPCT/CN2023/085071 | 2023-03-30 | ||
| CN2023085071 | 2023-03-30 | ||
| PCT/CN2023/091483 WO2023208173A1 (en) | 2022-04-29 | 2023-04-28 | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250004890A true KR20250004890A (ko) | 2025-01-08 |
Family
ID=88517887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247039643A Pending KR20250004890A (ko) | 2022-04-29 | 2023-04-28 | 사이클린 의존성 키나제 저해제로서의 치환된 6-(피리미딘-4-일)퀴놀린 화합물 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240300937A1 (enExample) |
| EP (1) | EP4514791A4 (enExample) |
| JP (1) | JP2025516213A (enExample) |
| KR (1) | KR20250004890A (enExample) |
| CN (2) | CN119095840A (enExample) |
| AR (1) | AR129185A1 (enExample) |
| AU (1) | AU2023260284A1 (enExample) |
| CA (1) | CA3256792A1 (enExample) |
| CL (1) | CL2024003269A1 (enExample) |
| CO (1) | CO2024014595A2 (enExample) |
| IL (1) | IL316556A (enExample) |
| MX (1) | MX2024013266A (enExample) |
| TW (1) | TW202400585A (enExample) |
| WO (1) | WO2023208173A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| EP4791727A1 (en) * | 2023-10-11 | 2026-08-19 | Beone Medicines I GmbH | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| WO2022149057A1 (en) * | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
-
2023
- 2023-04-28 IL IL316556A patent/IL316556A/en unknown
- 2023-04-28 JP JP2024563509A patent/JP2025516213A/ja active Pending
- 2023-04-28 KR KR1020247039643A patent/KR20250004890A/ko active Pending
- 2023-04-28 TW TW112115912A patent/TW202400585A/zh unknown
- 2023-04-28 WO PCT/CN2023/091483 patent/WO2023208173A1/en not_active Ceased
- 2023-04-28 CN CN202380036165.1A patent/CN119095840A/zh active Pending
- 2023-04-28 AU AU2023260284A patent/AU2023260284A1/en active Pending
- 2023-04-28 CA CA3256792A patent/CA3256792A1/en active Pending
- 2023-04-28 CN CN202510407101.9A patent/CN120441555A/zh active Pending
- 2023-04-28 EP EP23795605.7A patent/EP4514791A4/en active Pending
- 2023-04-28 AR ARP230101047A patent/AR129185A1/es unknown
-
2024
- 2024-04-01 US US18/623,847 patent/US20240300937A1/en active Pending
- 2024-10-25 CO CONC2024/0014595A patent/CO2024014595A2/es unknown
- 2024-10-25 MX MX2024013266A patent/MX2024013266A/es unknown
- 2024-10-25 CL CL2024003269A patent/CL2024003269A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129185A1 (es) | 2024-07-24 |
| CN120441555A (zh) | 2025-08-08 |
| IL316556A (en) | 2024-12-01 |
| MX2024013266A (es) | 2024-12-06 |
| AU2023260284A1 (en) | 2024-11-14 |
| EP4514791A4 (en) | 2026-03-11 |
| EP4514791A1 (en) | 2025-03-05 |
| CO2024014595A2 (es) | 2024-12-30 |
| CL2024003269A1 (es) | 2025-03-07 |
| CN119095840A (zh) | 2024-12-06 |
| US20240300937A1 (en) | 2024-09-12 |
| JP2025516213A (ja) | 2025-05-27 |
| CA3256792A1 (en) | 2023-11-02 |
| TW202400585A (zh) | 2024-01-01 |
| WO2023208173A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114127067B (zh) | 作为hpk1抑制剂的三环化合物及其用途 | |
| WO2022028492A1 (en) | Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors | |
| EP4291193A1 (en) | Egfr degraders and methods of use | |
| CN114096536A (zh) | 作为HPK1抑制剂的吡咯并[2,3-b]吡嗪及其用途 | |
| WO2021219070A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| WO2022068849A1 (en) | Bifunctional compounds for degradation of egfr and related methods of use | |
| TW202216686A (zh) | 藉由使ｅｇｆｒ抑制劑與ｅ３連接酶配位體結合來降解（ｅｇｆｒ）以及使用方法 | |
| WO2021180103A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| WO2021032148A1 (en) | Aminopyrazine compounds as hpk1 inhibitor and the use thereof | |
| KR20230002419A (ko) | Bcl-2 억제제 | |
| WO2022152233A1 (en) | Kras g12c inhibitors | |
| TW202212331A (zh) | 作為ｅｇｆｒ抑製劑之吲哚啉化合物及衍生物 | |
| WO2020020097A1 (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist | |
| US20240300937A1 (en) | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | |
| JP7406008B2 (ja) | Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途 | |
| WO2024230803A1 (en) | Isoquinolinone derivatives and 4h-quinolizinone derivatives and pharmarceutical compositions thereof for the treatment of disease | |
| EP4608826A1 (en) | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors | |
| US20250136586A1 (en) | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | |
| JP6977038B2 (ja) | Ｇｓｋ−３阻害剤 | |
| WO2025078995A1 (en) | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors | |
| CN117946077A (zh) | 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物 | |
| HK40061243A (en) | Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof | |
| HK40040196A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |